440 related articles for article (PubMed ID: 28412778)
1. PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
del Rivero J; Kohn EC
Oncology (Williston Park); 2017 Apr; 31(4):265-73. PubMed ID: 28412778
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells.
Senhaji Mouhri Z; Goodfellow E; Jean-Claude B
BMC Cancer; 2017 Aug; 17(1):540. PubMed ID: 28800752
[TBL] [Abstract][Full Text] [Related]
4. Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Kyle S; Thomas HD; Mitchell J; Curtin NJ
Br J Radiol; 2008 Oct; 81 Spec No 1():S6-11. PubMed ID: 18820000
[TBL] [Abstract][Full Text] [Related]
5. Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in
Sun C; Fang Y; Yin J; Chen J; Ju Z; Zhang D; Chen X; Vellano CP; Jeong KJ; Ng PK; Eterovic AKB; Bhola NH; Lu Y; Westin SN; Grandis JR; Lin SY; Scott KL; Peng G; Brugge J; Mills GB
Sci Transl Med; 2017 May; 9(392):. PubMed ID: 28566428
[TBL] [Abstract][Full Text] [Related]
6. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
7. Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair, and its deficiency sensitizes cells to poly(ADP-ribose) polymerase (PARP) inhibitor treatment.
Pan MR; Hsieh HJ; Dai H; Hung WC; Li K; Peng G; Lin SY
J Biol Chem; 2012 Feb; 287(9):6764-72. PubMed ID: 22219182
[TBL] [Abstract][Full Text] [Related]
8. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Dulaney C; Marcrom S; Stanley J; Yang ES
Semin Cell Dev Biol; 2017 Mar; 63():144-153. PubMed ID: 28087320
[TBL] [Abstract][Full Text] [Related]
10. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in cancer therapy using PARP inhibitors.
Kaur SD; Chellappan DK; Aljabali AA; Tambuwala M; Dua K; Kapoor DN
Med Oncol; 2022 Sep; 39(12):241. PubMed ID: 36180646
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors: its role in treatment of cancer.
Chen A
Chin J Cancer; 2011 Jul; 30(7):463-71. PubMed ID: 21718592
[TBL] [Abstract][Full Text] [Related]
13. Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.
Helleday T; Bryant HE; Schultz N
Cell Cycle; 2005 Sep; 4(9):1176-8. PubMed ID: 16123586
[TBL] [Abstract][Full Text] [Related]
14. The DNA damaging revolution.
Cetin B; Wabl CA; Gumusay O
Crit Rev Oncol Hematol; 2020 Dec; 156():103117. PubMed ID: 33059228
[TBL] [Abstract][Full Text] [Related]
15. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
Sandhu SK; Yap TA; de Bono JS
Curr Drug Targets; 2011 Dec; 12(14):2034-44. PubMed ID: 21777194
[TBL] [Abstract][Full Text] [Related]
17. The current status of PARP inhibitors in ovarian cancer.
McLachlan J; George A; Banerjee S
Tumori; 2016 Oct; 102(5):433-440. PubMed ID: 27716873
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Sunada S; Nakanishi A; Miki Y
Cancer Sci; 2018 Apr; 109(4):893-899. PubMed ID: 29427345
[TBL] [Abstract][Full Text] [Related]
19. LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Parvin S; Ramirez-Labrada A; Aumann S; Lu X; Weich N; Santiago G; Cortizas EM; Sharabi E; Zhang Y; Sanchez-Garcia I; Gentles AJ; Roberts E; Bilbao-Cortes D; Vega F; Chapman JR; Verdun RE; Lossos IS
Cancer Cell; 2019 Sep; 36(3):237-249.e6. PubMed ID: 31447348
[TBL] [Abstract][Full Text] [Related]
20. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Farmer H; McCabe N; Lord CJ; Tutt AN; Johnson DA; Richardson TB; Santarosa M; Dillon KJ; Hickson I; Knights C; Martin NM; Jackson SP; Smith GC; Ashworth A
Nature; 2005 Apr; 434(7035):917-21. PubMed ID: 15829967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]